Adient
ADNT · NYSE · Consumer Discretionary · United States
Financials at a glance
Source: SEC XBRLAnnual
Quarterly · last 8
Revenue (FY2025)
$14.5B
Net margin
-1.9%
ROE
-15.9%
Revenue CAGR (2y)
-2.8%
EPS (FY2025)
-3.39
Net profit (FY2025)
$-281.0M
Ask MarketChacha about ADNT
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Sep 2, 2026
No company-specific catalyst or filing was reported on September 2; the gain appears to reflect broader market or sector movement following recent negative analyst commentary.
· confidence: low - Sep 1, 2026
Adient shares fell 3.8% with no company-specific news or filing released on September 1; the move appears to reflect broader market or sector trading following recent analyst actions including a Zacks downgrade to Strong Sell and the stock trading below its 50-day moving average.
· confidence: low - Jul 28, 2026
No specific company catalyst or filing was reported on July 28; the gain appears to reflect broader market/sector movement and investor interest in the stock trading below fair value per recent analysis.
- Jul 27, 2026
No clear company-specific catalyst identified for the move; Adient rose with broader market/sector flows amid limited news flow.
source 1 ↗· confidence: low - Jul 22, 2026
No clear company-specific catalyst identified; the stock rose with broader market or sector moves.
· confidence: low
Daily moves with the verified reason behind them. Education only — not investment advice.
Financials
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2025 | $14.5B | $-281.0M | -3.39 | -1.9% | -15.9% |
| FY2024 | $14.7B | $18.0M | 0.20 | 0.1% | 0.8% |
| FY2023 | $15.4B | $205.0M | 2.15 | 1.3% | 9.2% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin |
|---|---|---|---|---|
| 2026Q2 | $3.9B | $25.0M | 0.32 | 0.6% |
| 2026Q1 | $3.9B | $27.0M | 0.34 | 0.7% |
| 2025Q4 | $3.6B | $-22.0M | -0.28 | -0.6% |
| 2025Q2 | $3.7B | $36.0M | 0.43 | 1.0% |
| 2025Q1 | $3.6B | $-335.0M | -3.99 | -9.3% |
| 2024Q4 | $3.5B | $0 | 0.00 | 0.0% |
| 2024Q2 | $3.7B | $-11.0M | -0.12 | -0.3% |
| 2024Q1 | $3.8B | $-70.0M | -0.77 | -1.9% |
| 2023Q4 | $3.7B | $20.0M | 0.21 | 0.5% |
| 2023Q2 | $4.1B | $73.0M | 0.77 | 1.8% |
| 2023Q1 | $3.9B | $-15.0M | -0.16 | -0.4% |
Figures as reported, in reporting currency. Source: SEC XBRL.
Filings & announcements
2026
- SEC8/5/2026
- SEC8/5/2026material
- SEC7/10/2026material
- SEC5/20/2026material
- SEC5/6/2026material
- SEC5/6/2026
- SEC3/13/2026material
- SEC2/10/2026material
- SEC2/4/2026material
- SEC2/4/2026
- SEC1/16/2026material
2025
- SEC11/18/2025
- SEC11/5/2025material
- SEC10/17/2025material
- SEC8/11/2025material
- SEC8/6/2025material
- SEC8/6/2025
In the news
- Adient (NYSE:ADNT) Given Average Rating of "Hold" by BrokeragesMarketBeat · 8/31/2026
- Adient PLC (ADNT) Key Financial Ratios – Valuation, Profitability & MoreValue Research · 8/30/2026
- Adient (NYSE:ADNT) Stock Price Passes Below 50-Day Moving Average - Time to Sell?MarketBeat · 8/29/2026
- ADNT | Adient plc Ordinary Shares Financials - Revenue BreakdownQuiver Quantitative · 8/23/2026
- Will Automation Spending and Plant Consolidation Shift Adient's (ADNT) Efficiency and Risk Narrative?simplywall.st · 8/22/2026
- Adient $ADNT Shares Purchased by Bank of America Corp DEMarketBeat · 8/21/2026
- Zacks Research Downgrades Adient (NYSE:ADNT) to Strong SellMarketBeat · 8/19/2026
- Adient (NYSE:ADNT) Given New $21.00 Price Target at Morgan StanleyMarketBeat · 8/18/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.